Agile Therapeutics Tightens Q2 Forecast For Contraceptive Patch 'Twirla'

  • Agile Therapeutics Inc AGRX expects Q2 FY22 Twirla demand to be at the mid-point of the earlier provided outlook of 20,000 - 22,000 cycles (new range 21,000 - 21,500 cycles).
  • It represents approximately 26% to 30% quarter-on-quarter growth. 
  • The updated Twirla demand guidance reflects continued progress in retail and non-retail channels. The non-retail channel shows significant quarter-over-quarter growth via the company's partnership with Afaxys.
  • Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive patch that contains the active ingredients levonorgestrel, a type of progestin, and ethinyl estradiol, a type of estrogen. 
  • Additionally, the company expects Q2 operating expenses to be $11.5 million - $12.5 million (prior view $12.5 million - $13.5 million).
  • The change is primarily attributable to optimizing the Twirla sales force and marketing efforts to focus on the most productive territories with high volume and favorable third-party reimbursement.
  • Price Action: AGRX shares are down 4.99% at $0.65 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!